Clinical trials: Decompensated Cirrhosis of Liver
Decompensated Cirrhosis, Fecal Microbiota Transplantation
Fecal Microbiota Transplantation for Decompensated Cirrhosis
Imbalance of gut bacteria is suspected to play a key role driving the progression of cirrhosis and there is hope manipulation of these bacteria may be beneficial.
- Trial name
- FMTDC (NCT03014505)
- Testing
- FMT, traditional treatments
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Chengdu Medical College
Chronic Hepatitis C
A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C
The primary objective of this program is to provide DCV for 24 weeks to be given in combination with SOF to subjects with chronic hepatitis C with decompensated cirrhosis or post-liver transplant subjects with chronic hepatitis C…
- Trial name
- NCT02161939
- Testing
- Daclatasvir (BMS-790052), Sofosbuvir
- Where
- 20 sites in United States
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) with or without ribavirin (RBV) for 12 weeks in adults with…
- Trial name
- NCT02996682
- Testing
- SOF/VEL, RBV
- Where
- 33 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Gilead Sciences
Hepatitis B, Decompensated Cirrhosis
Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
In this study, treatment-naïve HBV-related cirrhosis patients were retrospectively enrolled at the first episode of decompensation (ascites or variceal hemorrhage).
- Trial name
- NCT05086536
- Testing
- no intervention
- Where
- 7 sites in China
- Volunteers
- 600 people
- Sponsor
- Beijing Friendship Hospital
Decompensated Hepatitis B Cirrhosis
Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
This study aims to conduct a prospective, multicenter, double-blind, randomized, placebo-controlled trial. The planned sample size is 432 patients, with the ratio of the Fuzheng Huayu group to the placebo control group being 1:1.
- Trial name
- FZHYRORDFDHBLC (NCT07017426)
- Testing
- Fuzheng Huayu tablets
- Volunteers
- 432 people
- Sponsor
- Zhiyun Yang
Decompensated Cirrhosis, AKI - Acute Kidney Injury
Study to Evaluate the Efficacy of Intravenous Administration of Human Albumin Versus Saline Solution in Patients With descompénsate Cirrhosis Grade 1B or Higher Renal Failure
This is a phase IV, unicentric, open-label. Patients eligible for this study will be patients with AKI 1B or greater and decompensated cirrhosis from the hospital participating in the study
- Trial name
- LIVER-AKI (NCT07270874)
- Testing
- Saline solution (NaCl 0.9%)
- Volunteers
- 114 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Liver Cirrhosis
Autologous Bone Marrow Derived Stem Cells in Decompensate Cirrhotic Patients
Liver cirrhosis (LC) is the final outcome for chronic liver diseases. The liver transplantation is the sole effective therapy available to these patients.
- Trial name
- NCT01120925
- Testing
- MNC, CD133, Control
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Royan Institute
Decompensated Cirrhosis
CirrhoCare in COVID-19: A Pilot, Remote, Home Monitoring Study in Advanced Cirrhosis
The COVID-19 outbreak has exposed many strengths and weaknesses of delivering healthcare, and we want to assess whether patients with advanced liver cirrhosis can be effectively monitored at home, to limit hospital visits and…
- Trial name
- NCT05045924
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Cirrhosis, Ascites
Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis
Cirrhosis is frequently complicated by derangement of body fluid homeostasis resulting in accumulation of large amounts of extracellular fluid in the peritoneal cavity (ascites) and interstitial tissue (edema).
- Trial name
- NCT00511394
- Testing
- 20% Human Albumin, Normal Saline
- Where
- India
- Volunteers
- 16 people
- Sponsor
- Govind Ballabh Pant Hospital
Portal Hypertension
The Effect of Probiotics (VSL) on Portal Hypertension
The investigators will address the hypothesis that portal hypertension is mediated in part by bacterial or endotoxin translocation and the production of inflammatory mediators (tumor necrosis factor-α (TNFα), etc.).
- Trial name
- NCT01032941
- Testing
- Probiotic
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Decompensated Cirrhosis of Liver
Using Telemedicine to Assist in the Clinical Care of Patients With Decompensated Cirrhosis
The goal of this clinical trial is to learn if an integrated digital and telemedicine care model works to manage decompensated cirrhosis in patients.
- Trial name
- NCT07439770
- Testing
- Telemedicine care
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Hypertension, Portal, Liver Cirrhosis
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
This study is open to adults with advanced liver cirrhosis caused by hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis or other causes.
- Trial name
- NCT06082843
- Testing
- Avenciguat
- Where
- 15 sites in United States, Austria and 8 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Hyponatremia With Excess Extracellular Fluid Volume, Cirrhosis, Liver
Albumin for Management of Hypervolemic Hyponatremia (AlbuCAT)
resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value > 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
- Trial name
- AlbuCAT (NCT03941405)
- Testing
- Albumin treatment
- Where
- 3 sites in Spain
- Volunteers
- 52 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Cirrhosis, Acute Decompensation
Study of microRNAs in a Decompensated Cirrhosis
Cirrhotic patients are at higher risk of sepsis due to impaired innate and adaptive immune responses. Septic complications represent a major issue in the management of cirrhotic patients, with a 1-month mortality rate of 23%…
- Trial name
- EmiC (NCT03905746)
- Testing
- blood sample at Day 0, blood sample at Day 2 and Day 7, stool sample at Day 0
- Where
- France
- Volunteers
- 444 people
- Sponsor
- Hospices Civils de Lyon
Cirrhosis, Liver
Pathogenic Metagenomic Next-generation Sequencing to Optimize the Diagnosis of Decompensated Cirrhosis Infection
The goal of this observational study is to learn about clinical application of pathogenic metagenomic next-generation sequencing to optimize the diagnosis of infection in decompensated cirrhotic patients.
- Trial name
- NCT06039696
- Where
- China
- Volunteers
- 850 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Cirrhosis, Alcoholic, Progression
Prospective Cohort Study of Disease and Outcomes in Cirrhosis
A population based incidence cohort will enroll patients newly diagnosed with cirrhosis to investigate disease characteristics and outcomes, explore mechanisms predicting early death and hospital admission, and assess new…
- Conditions
- Liver Cirrhosis, Alcoholic, Progression, Liver Diseases, Decompensated Cirrhosis
- Trial name
- ProDoc (NCT04422223)
- Where
- Denmark
- Volunteers
- 550 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Decompensated Cirrhosis
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
Decompensated cirrhosis has a high overall mortality rate. There is a large unmet need for safe and alternative therapeutic potions.
- Trial name
- NCT05224960
- Testing
- UC-MSCs
- Where
- 7 sites in China
- Volunteers
- 140 people
- Sponsor
- Beijing 302 Hospital
Decompensated Cirrhosis
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1)
This is a Phase 1, open label, dose escalation clinical trial of human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis.
- Trial name
- NCT05227846
- Testing
- Human Umbilical Cord-derived Mesenchymal Stem Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing 302 Hospital
Decompensated Liver Cirrhosis
TIPS in Patients With Decompensated Liver Cirrhosis
This is a single center patient registry of patients receiving a transjugular intrahepatic portosystemic shunt (TIPS) at Hannover Medical School.
- Trial name
- NCT04801290
- Testing
- TIPS insertion
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- Hannover Medical School
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Prospective Validation Cohort 1
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD PVC1 (NCT06723275)
- Testing
- Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking
- Where
- 8 sites in Belgium, France and 3 more
- Volunteers
- 630 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris